Aarti Drugs Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings

Investors weighing an Aarti Drugs target price for 2027 should start with where the stock sits today. At Rs 412.40 on 9 October 2026, it is 22.8% below its 52-week high of Rs 534.00 and 29.3% above its 52-week low of Rs 318.95. That range spans 67% from low to high, so the entry point matters as much as the Aarti Drugs price forecast itself.

This article builds the Aarti Drugs share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 444 base case and the Rs 539 bull case were reached, along with a downside risk level of Rs 332.

Click Here – Get Free Investment Predictions

Aarti Drugs Stock Analysis: Company Overview and Key Stats

Aarti Drugs (NSE: AARTIDRUGS) has a market capitalisation of Rs 3,788 crore. In FY26 it reported revenue of Rs 2,568 crore and net profit of Rs 194.94 crore. The table collects the figures the Aarti Drugs share price target is built on.

Metric	Value
Company	Aarti Drugs
NSE Ticker	AARTIDRUGS
CMP (9 October 2026)	Rs 412.40
52-Week High	Rs 534.00
52-Week Low	Rs 318.95
Market Cap	Rs 3,788 crore
PE Ratio (TTM)	19.82
Industry PE	37.59
Price to Book	2.45
Return on Equity	12.58%
Debt to Equity	0.37
EPS (TTM)	Rs 20.94
Dividend Yield	0.48%
12-Month Base Target	Rs 444
Bull Case	Rs 539
Downside Risk Level (not a target)	Rs 332

Why Is Aarti Drugs Share Price Target Set at Rs 444 for 2027?

The base-case Aarti Drugs stock target of Rs 444 applies a PE multiple of 19.82 to a forward EPS estimate of Rs 22.41. That EPS assumes 7.0% yearly growth, the pace from FY24 to FY26, and puts the target 7.7% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Aarti Drugs Target Price: Five Years of Results

Aarti Drugs grew revenue from Rs 2,500 crore in FY22 to Rs 2,568 crore in FY26, a compound annual growth rate of 0.7%. Net profit grew more slowly, from Rs 205 crore to Rs 194.94 crore (-1.3% a year), which points to margin pressure alongside the sales growth.

Financial Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Dividend per Share (Rs)
FY22	2,499.96	205.00	22.12	1.00
FY23	2,718.25	166.36	17.97	1.00
FY24	2,532.61	171.59	18.65	1.00
FY25	2,403.39	168.10	18.35	1.00
FY26	2,567.70	194.94	21.36	2.00

FY26 revenue growth was 6.8%, faster than the four-year average of 0.7%, and net profit moved up 16.0%. EPS rose from Rs 18.65 in FY24 to Rs 21.36 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Aarti Drugs converted 7.6% of FY26 revenue into net profit, against 7.0% in FY25, within a five-year range of 6.1% to 8.2%. EBITDA margin was 12.1% in FY26 versus 12.6% in FY25.

In the June 2026 quarter, revenue was Rs 703.59 crore, up 19.1% from the same quarter a year earlier, while net profit of Rs 50.13 crore was down 7.1%. EBITDA came in at Rs 99.01 crore, up 33.1% year on year. The next quarterly result is the first test of whether the earnings assumption holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.37, and shareholders' equity grew from Rs 1,036 crore in FY22 to Rs 1,549 crore in FY26. Operating cash flow in FY26 was Rs 253.54 crore against capital expenditure of Rs 173.32 crore, leaving free cash flow of Rs 80.22 crore, or 2.1% of the current market capitalisation. In FY25 free cash flow was Rs 67.42 crore.

Valuation Check for the Aarti Drugs Stock Target: PE, Price to Book and ROE

At a PE of 19.82 against an industry PE of 37.59, Aarti Drugs trades at a discount to its industry. Price to book is 2.45 on a book value of Rs 169.70 per share, and return on equity is 12.58%. A PE of 19.82 equals an earnings yield of 5.0%, and the FY26 dividend of Rs 2.00 per share gives a yield of 0.48%.

Shareholding Pattern and Institutional Holding

Promoters held 54.43% of Aarti Drugs in June 2026, and promoter holding fell from 55.22% in June 2025 to 54.43% in June 2026. Foreign institutional investors (FII) held 1.52% and domestic institutions (DII) held 10.29%, which puts total institutional holding at 11.81%. FII holding fell from 2.26% in June 2025 to 1.52% in June 2026. Public shareholders own the remaining 33.75%.

Aarti Drugs Share Price Targets for the Short Term and 12 Months

Short Term Aarti Drugs Stock Target Levels: Technical Setup

At Rs 412.40 on 9 October 2026, Aarti Drugs trades below its 50-day simple moving average of Rs 422.28 and above its 200-day exponential moving average of Rs 407.89. The 14-day RSI reads 38.8, which is neutral territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 422.28 (50-day simple moving average) and the nearest support is Rs 407.89 (200-day exponential moving average). A sustained move above Rs 422.28 would improve the short-term setup, while a close below Rs 407.89 would shift attention to the next support.

12 Month Aarti Drugs Target Price for 2027

The 12-month target for Aarti Drugs is Rs 444: forward EPS of Rs 22.41 at a PE of 19.82. That is 7.7% above Rs 412.40. It would still leave the stock 16.9% below its 52-week high of Rs 534.00.

How EPS Growth and PE Multiple Change the Aarti Drugs Target Price

EPS Growth	PE 15.86	PE 19.82	PE 22.79
0.0% (EPS Rs 20.94)	Rs 332	Rs 415	Rs 477
7.0% (EPS Rs 22.41)	Rs 355	Rs 444	Rs 511
13.0% (EPS Rs 23.67)	Rs 375	Rs 469	Rs 539

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Aarti Drugs price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Aarti Drugs Stock Target in 2027

Bull Case Rs 539

The bull case Aarti Drugs price target needs EPS growth of 13.0%, which lifts forward EPS to Rs 23.67, and a PE multiple that rises 15% to 22.79. That gives Rs 539, 30.7% above the current price and above the 52-week high of Rs 534.00, so the stock would have to set a fresh 52-week high.

Downside Risk Level Rs 332

The downside risk level is not a target. It assumes EPS stays flat at Rs 20.94 and the PE falls 20% to 15.86. That gives Rs 332, 19.5% below the current price and above the 52-week low of Rs 318.95.

Scenario	EPS Growth	PE Multiple	Price (Rs)	Change vs CMP
Bull Case	13.0%	22.79	Rs 539	+30.7%
Base Case	7.0%	19.82	Rs 444	+7.7%
Downside Risk	0.0%	15.86	Rs 332	-19.5%

Key Risks to the Aarti Drugs Target Price for 2027

Growth Slowdown Risk for the Aarti Drugs Price Target

Revenue in the June 2026 quarter was up 19.1% year on year, and FY26 revenue growth was 6.8%. If growth slows from here, the EPS estimate behind the Aarti Drugs stock target will need revising.

Liquidity and Size Risk

Aarti Drugs has a market capitalisation of Rs 3,788 crore. Institutional holding is 11.81%, and promoters hold 54.43%. Stocks of this size can move sharply on small volumes, and exits can take longer than entries.

Valuation and Margin Risk

Net margin was 7.6% in FY26, so a small slip in costs moves profit noticeably. At a PE of 19.82 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 15.86 would cut the price even if earnings hold.

Market and Technical Risk

The stock trades 22.8% below its 52-week high, with an RSI of 38.8 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.

How to Invest in Aarti Drugs

Start with the live price and volume. Any Aarti Drugs share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 412.40 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Aarti Drugs' PE, ROE, debt and shareholding in one place.

Check Aarti Drugs fundamentals on the Univest Screener

Then compare the three Aarti Drugs target price scenarios with your own view. If you expect EPS growth below 7.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Aarti Drugs live price and get daily stock recommendations.

Conclusion

The Aarti Drugs share price target for 2027 is Rs 444 in the base case, with Rs 539 as the bull case. The support for that view is arithmetic you can check: EPS grew 7.0% a year over FY24 to FY26, and the stock trades at a PE of 19.82. The risks are equally concrete, including a stock that sits 22.8% below its 52-week high and a downside scenario that cuts the price 19% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.

FAQs on Aarti Drugs Share Price Target 2027

What is the Aarti Drugs share price target for 2027?

Ans. The base-case Aarti Drugs share price target for 2027 is Rs 444, with Rs 539 as the bull case. The downside risk level, which is not a target, is Rs 332. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.

What is the Aarti Drugs share price today?

Ans. As of 9 October 2026, 12:52 PM IST, Aarti Drugs trades at Rs 412.40, down 0.39% on the day. The 52-week range is Rs 318.95 to Rs 534.00.

Is Aarti Drugs a buy or sell at the current price?

Ans. The data is mixed rather than one-sided: EPS has grown 7.0% a year over FY24 to FY26, but the stock is 22.8% below its 52-week high. Whether Aarti Drugs fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.

What are the bull case target and downside risk level for Aarti Drugs shares?

Ans. The bull case target is Rs 539, which assumes 13.0% EPS growth and a PE of 22.79. The downside risk level is Rs 332, which assumes flat EPS and a PE of 15.86. It marks a risk, not a target.

What are the main risks to the Aarti Drugs price target?

Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 3,788 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.

What is the PE ratio of Aarti Drugs and how does it compare with the industry?

Ans. The PE ratio of Aarti Drugs is 19.82 against an industry PE of 37.59. Price to book is 2.45 and return on equity is 12.58%. The base case in the Aarti Drugs price target holds this PE constant.

Who owns Aarti Drugs, and what is the promoter holding?

Ans. Promoters held 54.43% of Aarti Drugs in June 2026. FII held 1.52%, DII held 10.29% and the public held 33.75%.

What were Aarti Drugs' latest quarterly results?

Ans. In the June 2026 quarter, Aarti Drugs reported revenue of Rs 703.59 crore (up 19.1% year on year) and net profit of Rs 50.13 crore (down 7.1%).